The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.

Hadji, Peyman; Ziller, May; Maurer, Tobias; Autenrieth, Michael; Muth, Mathias; Ruebel, Amelie; May, Christoph; Birkholz, Katrin; Diebel, Erhardt; Gleissner, Jochen; Rothe, Peter; Gschwend, Juergen E

Hadji, Peyman; Ziller, May; Maurer, Tobias; Autenrieth, Michael; Muth, Mathias; Ruebel, Amelie; May, Christoph; Birkholz, Katrin; Diebel, Erhardt; Gleissner, Jochen; Rothe, Peter; Gschwend, Juergen E.

Afiliação

Hadji P; Philipps-University of Marburg, Universitatsklinikum Giessen und Marburg, Marburg, Germany.
Ziller M; Philipps-University of Marburg, Universitatsklinikum Giessen und Marburg, Marburg, Germany.
Maurer T; Urologische Klinik, Klinikum rechts der Isar der Technische Universitaet Muenchen, Muenchen, Germany.
Autenrieth M; Urologische Klinik, Klinikum rechts der Isar der Technische Universitaet Muenchen, Muenchen, Germany.
Muth M; Novartis Pharma GmbH, BU Oncology, Nuernberg, Germany.
Ruebel A; Novartis Pharma GmbH, BU Oncology, Nuernberg, Germany.
May C; Novartis Pharma GmbH, Biostatistics and Medical Writing, Nuernberg, Germany.
Birkholz K; Novartis Pharma GmbH, BU Oncology, Nuernberg, Germany.
Diebel E; Outpatient Center, Magdeburg, Germany.
Gleissner J; Outpatient Center, Magdeburg, Germany.
Rothe P; Outpatient Center, Magdeburg, Germany.
Gschwend JE; Urologische Klinik, Klinikum rechts der Isar der Technische Universitaet Muenchen, Muenchen, Germany.

J Bone Oncol ; 1(3): 88-94, 2012 Dec.

Article em En | MEDLINE | ID: mdl-26909262

Palavras-chave

AE, adverse events; BC, breast cancer; Bone marker; Bone metastases; CTX; CTX, C-terminal cross-linking telopeptide of type I collagen; Cancer; CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ITT, intent-to-treat; NTX, urinary N-telopeptide; OPG, osteoprotegerin; P1NP; P1NP, amino-terminal propeptide of type I collagen; PC, prostate cancer; PSA, prostate-specific antigen; QoL, quality of life; RANKL, receptor activator of nuclear factor-κB ligand; SRE, skeletal-related event; ULN, upper limit of normal; VAS, visual analogue scale; ZOL, zoledronic acid; Zoledronic acid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article